2022 American Transplant Congress
Analysis of Induction Dose and Incidence of CMV Viremia in High Risk (HR; D+/R-) Renal Transplant Recipients
University of Pittsburgh Medical Center, Pittsburgh, PA
*Purpose: Depleting induction puts patients at risk of opportunistic infections. Our protocol aims for 5-6mg/kg cumulative dose of antithymocyte globulin(ATG) divided over 4 doses. It…2021 American Transplant Congress
Association Between Cumulative Antithymocyte Globulin Dosing and Adverse Outcomes in Pediatric Heart Transplant Recipients
*Purpose: Lymphocyte depletion via rabbit antithymocyte globulin (rATG) is the most frequently used induction immunosuppressive in pediatric orthotopic heart transplant (OHT). Although outcomes are often…2021 American Transplant Congress
Continuous 24-Hour Antithymocyte Globulin (ATG) for Renal Allograft Rejection: Results of a Randomized Controlled Trial
Houston Methodist Hospital, Houston, TX
*Purpose: For acute renal allograft rejection (AR), ATG is generally administered in the inpatient setting because of the need for intravenous access, patient monitoring, and…2021 American Transplant Congress
Dosing Weight of Rabbit Antithymocyte Globulin and Outcomes Among Kidney Transplant Patients Treated for Rejection
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
*Purpose: Rabbit antithymocyte globulin (rATG) is FDA approved for kidney transplant induction therapy and treatment of T-cell mediated rejection (TCMR). While prior studies comparing dosing…2021 American Transplant Congress
A Question with Multiple Answers: Do Renal Transplant Recipients Require Steroid Maintenance Following Thymoglobulin Induction?
Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Anti-thymocyte globulin (ATG) has been used with good results in renal transplantation as induction therapy, followed by triple immunosuppression with calcineurin inhibitors, antimetabolites, and…2021 American Transplant Congress
Outcomes in Standard vs. Extended Use of Thymoglobulin as Induction Therapy in Kidney Transplant Recipients
*Purpose: Thymoglobulin induction along with modern maintenance immunosuppression has been found to have a significant reduction in acute rejection in kidney transplantation. The recommended duration…2021 American Transplant Congress
No Benefit of Antithymocyte Globulin in Living Donor Liver Transplant Recipients
Baylor University Medical Center, Dallas, TX
*Purpose: Acute rejection after liver transplant is associated with increased risk of graft failure and mortality. Reports on rejection rates in living donor liver transplants…2020 American Transplant Congress
Comparison of Short-Term Outcomes of Induction Therapy with Alemtuzumab versus Rabbit Antithymocyte Globulin in Lung Transplantation
Pharmacy, Mayo Clinic, Jacksonville, FL
*Purpose: To identify the short-term efficacy and safety outcomes of alemtuzumab (C1H) versus rabbit antithymocyte globulin (rATG) in lung transplant patients. The objectives are to…2020 American Transplant Congress
A Recombinant, Fully Human ATG Polyclonal Antibody Drug Drives Immune Cell Depletion in a Model of Graft-versus-Host Disease
Immunology, GigaGen, South San Francisco, CA
*Purpose: Anti-thymocyte globulin (ATGs) are polyclonal antibody products that target and deplete T cells for immunosuppression in transplantation (prophylaxis of rejection). Since ATGs are derived…2020 American Transplant Congress
Depletional Profiles of Human and Rhesus Specific Anti-Thymocyte Globulins in Rhesus Macaques
*Purpose: Rabbit anti-human ATG (rATG; Thymoglobulin®) is the most commonly used formulation for depletional induction therapy in the United States. However, given that it is…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 8
- Next Page »